Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1984 1
1985 2
1986 2
1987 1
1988 1
1989 1
1990 1
1991 1
1993 1
1994 2
1995 2
1996 2
1998 1
1999 1
2000 1
2001 5
2002 4
2003 3
2004 4
2005 4
2006 5
2007 6
2008 5
2009 1
2010 3
2011 5
2012 5
2013 13
2014 9
2015 8
2016 7
2017 10
2018 8
2019 10
2020 17
2021 15
2022 13
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticu …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myelop …
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2022 Mar 1;97(3):352-372. doi: 10.1002/ajh.26455. Epub 2022 Jan 27. Am J Hematol. 2022. PMID: 34985762 Free article. Review.
The MMM stratifies CMML patients into four groups: high (3 risk factors), intermediate-2 (2 risk factors), intermediate-1 (1 risk factor), and low (no risk factors), with median survivals of 16, 31, 59, and 97 months, respectively. RISK-ADAPTED THERAPY: Hypom …
The MMM stratifies CMML patients into four groups: high (3 risk factors), intermediate-2 (2 risk factors), intermediate-1 (1 r …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations. ...GIPSS features four and MIPSSv2 five risk categori …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myelop …
Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E. Jacobsen E. Am J Hematol. 2022 Dec;97(12):1638-1651. doi: 10.1002/ajh.26737. Epub 2022 Oct 18. Am J Hematol. 2022. PMID: 36255040 Free article.
The presence of 0-1, 2, and 3 adverse factors defines low, intermediate, and high-risk disease. There are other clinical prognostic models but the FLIPI remains the most common. Other factors such as time to relapse of less than 2 years from chemoimmunotherapy and specific …
The presence of 0-1, 2, and 3 adverse factors defines low, intermediate, and high-risk disease. There are other clinical prognostic m …
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23. Am J Hematol. 2020. PMID: 32974939 Free article. Review.
RISK-ADAPTED THERAPY: The main goal of therapy in both PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once-daily or twice-daily aspirin (81 mg), in the absence of contraindications. …
RISK-ADAPTED THERAPY: The main goal of therapy in both PV and ET is to prevent thrombohemorrhagic complications. All patients …
Modern paradigms for prostate cancer detection and management.
Williams IS, McVey A, Perera S, O'Brien JS, Kostos L, Chen K, Siva S, Azad AA, Murphy DG, Kasivisvanathan V, Lawrentschuk N, Frydenberg M. Williams IS, et al. Med J Aust. 2022 Oct 17;217(8):424-433. doi: 10.5694/mja2.51722. Epub 2022 Oct 2. Med J Aust. 2022. PMID: 36183329 Free PMC article. Review.
Prostatectomy and definitive radiation remain the gold standard for localised intermediate and high risk disease. However, focal therapy is an emerging experimental treatment modality in Australia in carefully selected patients. The management of advanced prostate c …
Prostatectomy and definitive radiation remain the gold standard for localised intermediate and high risk disease. However, focal t …
Follicular lymphoma: 2020 update on diagnosis and management.
Freedman A, Jacobsen E. Freedman A, et al. Am J Hematol. 2020 Mar;95(3):316-327. doi: 10.1002/ajh.25696. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31814159 Free article. Review.
Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. Extranodal involvement is less common. ...Other factors such as time to relapse of less than 2 years from chemoimmunotherapy and specific gene mutations may also be …
Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. Extranodal involvement is …
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38269572 Review.
The triple A survival risk model, based on Age, Absolute neutrophil count, and Absolute lymphocyte count, effectively delineates high-, intermediate-1-, intermediate-2-, and low-risk disease with corresponding median survivals of 8, 14, 21, and 47 years. ...Cytoredu …
The triple A survival risk model, based on Age, Absolute neutrophil count, and Absolute lymphocyte count, effectively delineates high-, i …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.
Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea. Ruxolitinib is rec …
Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are r …
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Myelofibrosis is a BCR-ABL1-negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. ...Until the recent approva …
Myelofibrosis is a BCR-ABL1-negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary he …
178 results